Apogee Therapeutics (APGE) Other Gross PP&E Adjustments (2023 - 2026)
Apogee Therapeutics (APGE) reported Other Gross PP&E Adjustments of -$4.6 million for Q1 2026, up 54.14% year-over-year from -$3.0 million in Q1 2025, and up 58.68% on a QoQ basis from -$11.2 million in Q4 2025.
Apogee Therapeutics (APGE) has 4 years of Other Gross PP&E Adjustments data on file, last reported at -$4.6 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments rose 54.14% year-over-year to -$4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.6 million (up 54.14% YoY) and the FY2025 annual result came in at -$11.2 million, up 12.78% from the prior year.
- Other Gross PP&E Adjustments climbed to -$4.6 million in Q1 2026 per APGE's latest filing, from -$11.2 million in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$2.0 million in Q1 2024 and bottomed at -$12.9 million in Q4 2024.
- The 4-year median for Other Gross PP&E Adjustments is -$8.5 million (2025), against an average of -$7.6 million.
- The widest annual swing landed in 2024, when Other Gross PP&E Adjustments plunged 534.45%; it then jumped 54.14% in 2026.
- Tracing APGE's Other Gross PP&E Adjustments over 4 years: stood at -$2.0 million in 2023, then sank by 534.45% to -$12.9 million in 2024, then gained by 12.78% to -$11.2 million in 2025, then surged by 58.68% to -$4.6 million in 2026.
- Per Business Quant, the three latest APGE Other Gross PP&E Adjustments figures stand at -$4.6 million (Q1 2026), -$11.2 million (Q4 2025), and -$7.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Apogee Therapeutics | 5.53 Bn | 4.47 Bn | - | -4.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.63 Mn |
| Mar 31, 2026 | -4.63 Mn |
| Dec 31, 2025 | -11.21 Mn |
| Dec 31, 2025 | -11.21 Mn |
| Sep 30, 2025 | -7.89 Mn |
| Sep 30, 2025 | -7.89 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Jun 30, 2025 | -9.18 Mn |
| Mar 31, 2025 | -10.10 Mn |
| Mar 31, 2025 | -10.10 Mn |
| Dec 31, 2024 | -12.85 Mn |
| Dec 31, 2024 | -12.85 Mn |
| Sep 30, 2024 | -11.88 Mn |
| Sep 30, 2024 | -11.88 Mn |
| Jun 30, 2024 | -4.23 Mn |
| Jun 30, 2024 | -4.23 Mn |
| Mar 31, 2024 | -1.95 Mn |
| Mar 31, 2024 | -1.95 Mn |
| Dec 31, 2023 | -2.03 Mn |
| Dec 31, 2023 | -2.03 Mn |